Lactoferrin enhanced efficacy of the BCG vaccine to generate host protective responses against challenge with virulent Mycobacterium tuberculosis.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a disease with world wide consequences, affecting nearly a third of the world's population. The established vaccine for TB, an attenuated strain of Mycobacterium bovis Calmette Guerin (BCG), has existed since 1921. Lactoferrin, an iron-binding protein found in mucosal secretions and granules of neutrophils was hypothesized to be an ideal adjuvant to enhance the efficacy of the BCG vaccine, specifically because of previous reports of lactoferrin enhancement of IL-12 production from macrophages infected with BCG. Different vaccination protocols were investigated for generation of host protective responses against MTB infection using lactoferrin admixed to the BCG vaccine. Resulting effects demonstrate that BCG/lactoferrin increased host protection against MTB infection by decreasing organ bacterial load and reducing lung histopathology; significant reduction in tissue CFUs and pathology were observed post-challenge compared to those seen with BCG alone. Addition of lactoferrin to the vaccine led to reduced pathological damage upon subsequent infection with virulent MTB, with positive results demonstrated when admixed in oil-based vehicle (incomplete Freund's adjuvant, IFA) or when given with BCG in saline. The observed post-challenge results paralleled increasing production of IFN-gamma and IL-6, but only limited changes to proinflammatory mediators TNF-alpha or IL-1beta from BCG-stimulated splenocytes. Overall, these studies indicate that lactoferrin is a useful and effective adjuvant to improve efficacy of the BCG vaccine, with potential to reduce related tissue damage and pulmonary histopathology.
Hwang
Shen-An
SA
Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, TX 77030, United States.
Wilk
Katarzyna M
KM
Budnicka
Monika
M
Olsen
Margaret
M
Bangale
Yogesh A
YA
Hunter
Robert L
RL
Kruzel
Marian L
ML
Actor
Jeffrey K
JK
D000818:Animals; D000941:Antigens / Q000276:immunology; D001500:BCG Vaccine / Q000276:immunology*; D004304:Dosage Forms; D005260:Female; D007117:Immunization, Secondary; D007371:Interferon-gamma / Q000235:genetics; D007781:Lactoferrin / Q000276:immunology*; D008168:Lung / Q000276:immunology / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D009169:Mycobacterium tuberculosis / Q000276:immunology* / Q000472:pathogenicity*; D009928:Organ Specificity / Q000276:immunology; D012333:RNA, Messenger / Q000235:genetics; D013154:Spleen / Q000276:immunology / Q000382:microbiology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
D000941:Antigens; D001500:BCG Vaccine; D004304:Dosage Forms; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma; D007781:Lactoferrin
Pediatrics. 1995 Jul;96(1 Pt 1):29-35
7596718
Immunol Today. 1995 Sep;16(9):417-9
7546203
Biochem Cell Biol. 2002;80(1):1-6
11908632
Int Immunopharmacol. 2002 Mar;2(4):475-86
11962727
Exp Dermatol. 2002 Apr;11(2):126-34
11994139
Arch Immunol Ther Exp (Warsz). 2002;50(6):399-410
12546066
Infect Immun. 2003 Apr;71(4):1656-61
12654778
Nat Med. 2003 May;9(5):533-9
12692540
Genome Res. 1996 Oct;6(10):986-94
8908518
Genome Res. 1996 Oct;6(10):995-1001
8908519
J Immunol. 1997 Jan 1;158(1):330-7
8977207
J Exp Med. 1997 Jul 7;186(1):39-45
9206995
Biochem Mol Biol Int. 1997 Sep;43(1):79-87
9315285
Eur J Immunol. 1997 Dec;27(12):3182-90
9464804
Int J Tuberc Lung Dis. 1998 Mar;2(3):200-7
9526191
J Dairy Res. 1998 May;65(2):283-93
9627847
J Immunol. 1999 Mar 15;162(6):3504-11
10092807
Int Immunopharmacol. 2005 Mar;5(3):591-9
15683854
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):107-14
15687034
Vaccine. 2005 Mar 18;23(17-18):2109-14
15755580
Clin Chest Med. 2005 Jun;26(2):167-82, v
15837103
ILAR J. 2005;46(3):280-93
15953835
Microbes Infect. 2005 May;7(5-6):962-7
15890555
J Exp Med. 2005 Jun 20;201(12):1915-24
15955839
Curr Opin Immunol. 2005 Aug;17(4):374-80
15963709
J Virol. 2005 Oct;79(20):12871-9
16188989
Vaccine. 2005 Dec 1;23(48-49):5526-32
16105710
Trends Immunol. 2005 Dec;26(12):660-7
16246622
J Interferon Cytokine Res. 1999 Oct;19(10):1183-93
10547159
Tuber Lung Dis. 1999;79(4):243-50
10692993
Clin Infect Dis. 2000 Jun;30 Suppl 3:S266-70
10875797
Immunol Cell Biol. 2000 Aug;78(4):334-41
10947857
Scand J Immunol. 2000 Oct;52(4):369-79
11013008
J Mol Endocrinol. 2000 Oct;25(2):169-93
11013345
Clin Infect Dis. 2000 Sep;31 Suppl 3:S64-7
11010824
Immunol Lett. 2000 Nov 1;74(3):183-8
11064098
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8
11095745
Trends Cell Biol. 2000 Dec;10(12):542-50
11121747
Annu Rev Immunol. 2001;19:93-129
11244032
Scand J Immunol. 2001 May;53(5):464-74
11309154
Tuberculosis (Edinb). 2001;81(1-2):141-6
11463235
J Immunol. 2001 Dec 15;167(12):6957-66
11739515
J Immunol. 2002 Feb 1;168(3):1322-7
11801672
J Leukoc Biol. 2002 Feb;71(2):271-8
11818448
Lancet Infect Dis. 2002 Feb;2(2):86-92
11901655
Infect Immun. 2006 Jan;74(1):557-65
16369012
Clin Vaccine Immunol. 2006 Feb;13(2):239-45
16467332
Infect Immun. 2006 Apr;74(4):2128-37
16552042
Med Microbiol Immunol. 2007 Sep;196(3):171-80
17377816
Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10188-92
7901851
Int J Parasitol. 2003 May;33(5-6):547-54
12782054
Scand J Immunol. 2003 Oct;58(4):449-61
14507310
J Immunol. 2003 Nov 1;171(9):4750-7
14568951
Curr HIV Res. 2003 Jul;1(3):309-20
15046255
Biosci Biotechnol Biochem. 2004 Mar;68(3):537-44
15056884
Vaccine. 2004 Mar 29;22(11-12):1498-508
15063575
Vaccine. 2004 Feb 25;22(8):1063-71
15161084
J Interferon Cytokine Res. 2004 Jun;24(6):362-71
15212710
Biometals. 2004 Jun;17(3):231-4
15222470
J Exp Med. 1970 Mar 1;131(3):559-70
5413328
Cell. 1989 Mar 10;56(5):731-40
2647299
Arch Dis Child. 1992 May;67(5):657-61
1599309
Eur J Clin Nutr. 1993 Apr;47(4):232-41
8491159
J Exp Med. 1993 Dec 1;178(6):2243-7
8245795
Eur J Immunol. 1994 Apr;24(4):793-8
7908633
Immunology. 1995 Mar;84(3):423-32
7751026